ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 352

Meta-Analysis: Influence of Methotrexate, Anti-TNF and Rituximab On the Immune Response to Influenza and Pneumococcal Vaccines in Patients with Rheumatoïd Arthritis

Charlotte Hua1, Thomas Barnetche2, Bernard Combe3 and Jacques Morel4, 1Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, 2Rheumatology, CHU Bordeaux Pellegrin, Bordeaux, France, 3Rheumatology, Hopital Lapeyronie, Montpellier, France, 4Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: anti-TNF therapy, methotrexate (MTX), Rheumatoid arthritis (RA), rituximab and vaccines

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Clinical Aspects I: Drug Studies/Drug Safety/Drug Utilization/Disease Activity & Remission

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Vaccines against influenza and streptococcus pneumonia are currently recommended for patients with rheumatoid arthritis (RA). This meta-analysis assesses current literature data on the impact of methotrexate (MTX), anti-TNF or rituximab (RTX) on the humoral response to pneumococcal and influenza vaccines in RA patients.

Methods:

Data sources were Medline, Embase and Cochrane databases and ACR 2011 abstracts. To be included, studies had to contain a group of RA patients treated with MTX, anti-TNF or RTX and a control group of RA patients without the treatment of interest. Both groups had to receive either pneumococcal or influenza vaccine. Results had to show rates of responders based on the antibody response ratio, corresponding to the level of antibodies measured at 1 month following vaccination as numerator and the level of antibodies at vaccination as denominator, for pneumococcal serotypes 6B and 23F or one of the 3 strains of influenza virus: H1N1, H3N2 and B. Out of 59 potentially relevant studies, 11 met inclusion criteria. Odds-ratios and their 95% confidence intervals were pooled using the generic inverse variance method. The heterogeneity between studies was assessed using the Cochran’s Q-test and the I2value, and a random effect model was performed if necessary. All the analyses were realized with the RevMan software 5.1 version. A significant statistical threshold of 0.05 was used.

Results: 

Following pneumococcal vaccination: response was reduced in patients treated with anti-TNF + MTX compared to those treated with anti-TNF not combined with MTX (pooled odds-ratio (OR) = 0.58; 95% confidence interval (CI) 0.36-0.94; p=0.03 for 23F and 0.33; 95% CI 0.20-0.54; p<0.0001 for 6B). Rates of responders were similar in patients under MTX alone and those treated with  MTX +anti-TNF (OR = 1.21; 95% CI 0.83-1.75 for 23F and 0.96; 95% CI 0.57-1.59 for 6B). The immune response was lower in patients treated with RTX, combined in most cases with MTX, than in patients under MTX as monotherapy (OR = 0.22; 95% CI 0.11-0.47; p<0.0001 for 23F and 0.25; 95% CI 0.11-0.58; p=0,001 for 6B).

Following influenza vaccination:proportion of responders was not different between patients treated with MTX and those not treated with MTX (OR= 1.36 ; 95%CI 0.69-2.68 for H1N1, 1.33; 95%CI 0.70-2.53 for H3N2, 1.28; 95%CI 0.64-2.56 for B). Response was decreased in patients under PBO+MTX versus patients under PBO not combined with MTX (OR for responders to at least 2 strains = 0.35; 95% CI 0.18-0.66; p=0.001). Patients treated with anti-TNF with or without MTX had same responders rates than patients whose treatment did not include anti-TNF (OR for responders to at least 2 strains = 0.42; 95% CI 0.17-1.09). Patients under RTX in monotherapy or in combination with DMARDs had a disminished humoral response compared to patients treated with DMARDs without RTX, significance being reached for H3N2 and B (OR = 0.11; 95% CI 0.04-0.31; p<0.0001 and 0.29; 95% CI 0.10-0.81; p=0.02).

Conclusion:

Immune response to both vaccines is reduced with RTX but not with anti-TNF. MTX decreased immunogenicity of pneumococcal vaccine whereas results about influenza vaccine are less homogeneous but suggest an impairment of the response due to MTX therapy.


Disclosure:

C. Hua,
None;

T. Barnetche,

Roche CHUGAI,

8;

B. Combe,

Merck Pharmaceuticals,

5,

Pfizer Inc,

5,

UCB,

5,

Roche Pharmaceuticals,

5,

Merck Pharmaceuticals,

8,

Pfizer Inc,

8,

Roche Pharmaceuticals,

8,

UCB,

8;

J. Morel,

Roche CHUGAI,

5,

Roche Pharmaceuticals,

2,

Bristol-Myers Squibb,

5,

UCB,

5,

Pfizer Inc,

2,

Pfizer Inc,

2,

Abbott Laboratories,

5,

Merck Pharmaceuticals,

5,

Amgen,

5,

Pfizer Inc,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/meta-analysis-influence-of-methotrexate-anti-tnf-and-rituximab-on-the-immune-response-to-influenza-and-pneumococcal-vaccines-in-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology